Literature DB >> 22431808

Expanding access to treatment for hepatitis C in resource-limited settings: lessons from HIV/AIDS.

Nathan Ford1, Kasha Singh, Graham S Cooke, Edward J Mills, Tido von Schoen-Angerer, Adeeba Kamarulzaman, Philipp du Cros.   

Abstract

The need to improve access to care and treatment for chronic hepatitis C virus (HCV) infection in resource-limited settings is receiving increasing attention. Key priorities for scaling up HCV treatment and care include reducing the cost of current and future treatment; simplifying the package of care; identifying opportunities to shift specific tasks to nonspecialists to overcome human resource constraints; service integration with human immunodeficiency virus (HIV) clinics, prison health services, and needle syringe and oral substitution therapy programs; improving surveillance, monitoring, and research; encouraging patient and community engagement; focusing specifically on the needs of vulnerable groups; and increasing financial and political commitment. Many of these obstacles have been addressed in rolling out treatment for human immunodeficiency virus during the last decade, and a number of lessons can be drawn to help improve access to HCV care.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431808     DOI: 10.1093/cid/cis227

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  35 in total

Review 1.  Milestones along the road of infection prevention in Egypt.

Authors:  H A El-Mahallawy; L M Mohsen; M Wassef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-08-01       Impact factor: 3.267

2.  Overcoming barriers to hepatitis C elimination.

Authors:  Manuel Mendizabal; Cristina Alonso; Marcelo O Silva
Journal:  Frontline Gastroenterol       Date:  2019-02-01

3.  Pegylated interferon pharmacokinetics and self-reported depressive symptoms during antiviral treatment for chronic hepatitis C.

Authors:  D M Evon; D E Esserman; M A Howell; R A Ruffin
Journal:  Pharmacopsychiatry       Date:  2014-08-14       Impact factor: 5.788

Review 4.  HCV management in resource-constrained countries.

Authors:  Seng Gee Lim
Journal:  Hepatol Int       Date:  2017-02-21       Impact factor: 6.047

Review 5.  Functional foods effective for hepatitis C: Identification of oligomeric proanthocyanidin and its action mechanism.

Authors:  Yo-Ichi Ishida; Masahiko Takeshita; Hiroaki Kataoka
Journal:  World J Hepatol       Date:  2014-12-27

6.  An Epidemiologic Investigation of a Case of Acute Hepatitis E.

Authors:  Souvik Sarkar; Elenita M Rivera; Ronald E Engle; Hanh T Nguyen; Cathy A Schechterly; Harvey J Alter; T Jake Liang; Robert H Purcell; Jay H Hoofnagle; Marc G Ghany
Journal:  J Clin Microbiol       Date:  2015-09-02       Impact factor: 5.948

7.  Cost-Effectiveness Modelling of Sofosbuvir-Containing Regimens for Chronic Genotype 5 Hepatitis C Virus Infection in South Africa.

Authors:  Ilanca Fraser; Johanita Burger; Martie Lubbe; George Dranitsaris; Mark Sonderup; Tienie Stander
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

Review 8.  Hepatitis C genotype 4: The past, present, and future.

Authors:  Tawhida Y Abdel-Ghaffar; Mostafa M Sira; Suzan El Naghi
Journal:  World J Hepatol       Date:  2015-12-08

Review 9.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

Review 10.  Antiviral treatment of hepatitis C.

Authors:  Eoin R Feeney; Raymond T Chung
Journal:  BMJ       Date:  2014-07-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.